Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0016053 (fibromyalgia)
 4,687 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fibromyalgia is a syndrome of musculoskeletal pain and tenderness in specific sites, fatigue, and sleep disturbance. Fibromyalgia may occur in patients with rheumatoid arthritis and other connective tissue diseases. Despite the fact that fibromyalgia patients may have alterations in the hypothalamic-pituitary-adrenal axis, no relationship had been established between fibromyalgia and diseases of the adrenal cortex. We report a case of a 46-year-old woman who presented with a new onset of a fibromyalgia-like syndrome meeting all American College of Rheumatology criteria except chronicity. Additional clinical features, including skin pigmentation, mild hypertension, and hyponatremia, as well as further laboratory testing led to a diagnosis of autoimmune Addison's disease. After steroid replacement, the symptoms of fibromyalgia disappeared. This is the first case in English-language literature of fibromyalgia secondary to Addison's disease. We suggest Addison's disease should be considered in the differential diagnosis of any patient with a fibromyalgia-like syndrome.
 ...
PMID:Fibromyalgia-Like Syndrome Secondary to Addison's Disease. 1907 45

We present the case of a 33-year-old female with generalized pain in the musculoskeletal system, fatigue, and many other symptoms. She was initially diagnosed with fibromyalgia but other tests finally confirmed Addison's disease. Supplementation with adrenal hormones resulted in total remission of pain and of other symptoms. This case serves to illustrate diagnostic pitfalls in patients with a generalized pain syndrome.
 ...
PMID:[Addison's disease imitating fibromyalgia]. 2136 46

Objective: To determine if patient self-administration of hydrocortisone will safely achieve superior symptom control for all hydrocortisone-responding disorders as it does for Addison's disease and rheumatoid arthritis. Methods: Two thousand four hundred and twenty-eight participants with hydrocortisone-responding disorders were brought to a minimum symptom state using daily administered hydrocortisone tablets in a 24-week, open study. Thereafter, participants used 5-day, low-dose hydrocortisone regimens to quench subsequent disorder exacerbations (flares) to maintain the minimum symptom state. Stressors such as emotional traumas, infections, allergies, and injuries were minimized to reduce disorder intensity, hydrocortisone consumption, and participant discomfort. Results: Two thousand fifteen participants, 601 with fibromyalgia, 579 with osteoarthritis, 246 with rheumatoid arthritis, 226 with undifferentiated arthritis, 75 with back pain, 51 with Parkinson's disease, 44 with polymyalgia rheumatica, 25 with neuropathy, 25 with chronic fatigue syndrome, 25 with dementia, 21 with migraine headache, 19 with multiple sclerosis, and 78 with other disorders completed the 24-week study to achieve a composite average symptom improvement of 76% with equal response rates. The participants averaged ingesting 12 mg of hydrocortisone per day. No significant adverse reactions were observed. Conclusions: Patient self-administration of hydrocortisone safely achieves superior symptom control for 38 hydrocortisone-responding disorders at equal rates and symptom improvements to confirm and amplify an earlier double-blind study finding on rheumatoid arthritis. These results are consistent with the body having an inflammation control system and chronic inflammation being a disorder unto itself with differing symptoms sets dependent on its location. Clinical Trials Government Identifier: NCT03558971.
 ...
PMID:General theory of inflammation: patient self-administration of hydrocortisone safely achieves superior control of hydrocortisone-responding disorders by matching dosage with symptom intensity. 3254 52